Comparison of Evolocumab and Ezetimibe, Both Combined with Statin Therapy, for Patients with Recent Acute Coronary Syndrome: A Cost-Effectiveness Analysis from the Chinese Healthcare Perspective.

Xiaoyu XiXin WangWenwen XieYu JiaSantiago Zuluaga SanchezLaura MartinezQuanming Zhao

Published in: Cardiovascular drugs and therapy (2022)

Compared with ezetimibe + statins, the combination of evolocumab + statins was found to be cost-effective at a threshold of 217,341 yuan (three times per capita GDP, 2020) in patients with recent ACS events in China.

Keyphrases

acute coronary syndrome
cardiovascular disease
healthcare
low density lipoprotein
percutaneous coronary intervention
antiplatelet therapy
coronary artery disease
atrial fibrillation
health information
social media